View Future GrowthA SPAC III Acquisition 과거 순이익 실적과거 기준 점검 5/6AC III Acquisition의 연간 평균 수익은 85.5%였으며, Capital Markets 산업의 수익은 연간 6.1% 증가했습니다.핵심 정보85.46%순이익 성장률106.04%주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률n/a자기자본이익률24.86%순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 29A SPAC III Acquisition Corp. Announces Notice of Non-Compliance with Nasdaq Listing RulesOn May 20, 2026, A SPAC III Acquisition Corp. (the Company) received a letter from The Nasdaq Stock Market LLC (Nasdaq), which stated that because the stockholders' equity of the Company reported on its Form 10-Q for the fiscal quarter ended March 31, 2026 was below the minimum of $2,500,000 stockholders' equity (the Minimum Stockholders' Equity Requirement) required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1), the Company no longer complies with Nasdaq's continued listing rules on The Nasdaq Capital Market. In accordance with the Nasdaq listing rules, the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Company is currently working on a compliance plan and plans to submit it to Nasdaq within the specified period. There is no assurance that the Company will be able to regain compliance with the Minimum Shareholders' Equity Requirement or that its compliance plan will be accepted by Nasdaq.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$12.80, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 39x in the Capital Markets industry in the US. Total returns to shareholders of 27% over the past year.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$13.11, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 22x in the Capital Markets industry in the US. Total returns to shareholders of 31% over the past year.Board Change • Jan 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jan 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$14.43, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 45% over the past year.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to US$21.63, the stock trades at a trailing P/E ratio of 46.2x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 117% over the past year.Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$13.00, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 26x in the Capital Markets industry in the US.New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$24.5m market cap).Board Change • Aug 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • May 28Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction.Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction on May 23, 2025. Pursuant to the terms of the Merger Agreement, the aggregate consideration to be paid to existing shareholders and holders of equity awards of Bioserica is $200 million, which will be paid entirely in stock, comprised of newly issued Class B Ordinary Shares of the Purchaser at a price of $10.00 per share, plus such number of Purchaser Class A Ordinary Shares as determined pursuant to the Merger Agreement, up to a maximum of 1,786,000 Purchaser Class A Ordinary Shares. Upon the effectiveness of the Acquisition Merger, all issued and outstanding ordinary shares of Bioserica will be cancelled and automatically converted into the right to receive, without interest, the applicable number and class of the ordinary shares of the Purchaser. A SPAC III (Holdings) Corp., holder of the Parent’s Class B ordinary share, has at least one (1) demand registration right for its registrable securities. The deal is subject to regulatory approvals. Norton Rose Fulbright acted as legal advisor to Bioserica International, Loeb & Loeb LLP acted as legal advisor to A SPAC III Acquisition Corp.Board Change • Jan 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역A SPAC III Acquisition가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:ASPC 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 26011031 Dec 25011030 Sep 25011030 Jun 25011031 Mar 25001031 Dec 24001030 Sep 24000031 Dec 230000양질의 수익: ASPC는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 지난 1년 동안 ASPC의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ASPC의 수익은 지난 5년 동안 연평균 85.5%로 크게 증가했습니다.성장 가속화: 지난 1년간 ASPC 의 수익 증가율(328%)은 연간 평균(85.5%)을 초과합니다.수익 대 산업: ASPC의 지난 1년 수익 증가율(328%)은 Capital Markets 업계의 38.3%를 상회했습니다.자기자본이익률높은 ROE: ASPC의 자본 수익률(24.9%)은 높음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/21 21:56종가2026/06/18 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스A SPAC III Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 29A SPAC III Acquisition Corp. Announces Notice of Non-Compliance with Nasdaq Listing RulesOn May 20, 2026, A SPAC III Acquisition Corp. (the Company) received a letter from The Nasdaq Stock Market LLC (Nasdaq), which stated that because the stockholders' equity of the Company reported on its Form 10-Q for the fiscal quarter ended March 31, 2026 was below the minimum of $2,500,000 stockholders' equity (the Minimum Stockholders' Equity Requirement) required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1), the Company no longer complies with Nasdaq's continued listing rules on The Nasdaq Capital Market. In accordance with the Nasdaq listing rules, the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Company is currently working on a compliance plan and plans to submit it to Nasdaq within the specified period. There is no assurance that the Company will be able to regain compliance with the Minimum Shareholders' Equity Requirement or that its compliance plan will be accepted by Nasdaq.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$12.80, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 39x in the Capital Markets industry in the US. Total returns to shareholders of 27% over the past year.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$13.11, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 22x in the Capital Markets industry in the US. Total returns to shareholders of 31% over the past year.
Board Change • Jan 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jan 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$14.43, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 45% over the past year.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to US$21.63, the stock trades at a trailing P/E ratio of 46.2x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 117% over the past year.
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$13.00, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 26x in the Capital Markets industry in the US.
New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$24.5m market cap).
Board Change • Aug 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • May 28Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction.Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction on May 23, 2025. Pursuant to the terms of the Merger Agreement, the aggregate consideration to be paid to existing shareholders and holders of equity awards of Bioserica is $200 million, which will be paid entirely in stock, comprised of newly issued Class B Ordinary Shares of the Purchaser at a price of $10.00 per share, plus such number of Purchaser Class A Ordinary Shares as determined pursuant to the Merger Agreement, up to a maximum of 1,786,000 Purchaser Class A Ordinary Shares. Upon the effectiveness of the Acquisition Merger, all issued and outstanding ordinary shares of Bioserica will be cancelled and automatically converted into the right to receive, without interest, the applicable number and class of the ordinary shares of the Purchaser. A SPAC III (Holdings) Corp., holder of the Parent’s Class B ordinary share, has at least one (1) demand registration right for its registrable securities. The deal is subject to regulatory approvals. Norton Rose Fulbright acted as legal advisor to Bioserica International, Loeb & Loeb LLP acted as legal advisor to A SPAC III Acquisition Corp.
Board Change • Jan 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.